Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer

(2011) E. Razis et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy

(2011) Phuong K. Morrow et al.   JOURNAL OF CLINICAL ONCOLOGY

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

PTEN, PIK3CA, p-AKT, and p-p70S6K Status

(2010) Francisco J. Esteva et al.   AMERICAN JOURNAL OF PATHOLOGY

“Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?

(2010) Nadia Margariti et al.   BREAST CANCER RESEARCH AND TREATMENT

Evolving Strategies for Overcoming Resistance to HER2-Directed Therapy: Targeting the PI3K/Akt/mTOR Pathway

(2010) Rita Nahta et al.   Clinical Breast Cancer

Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers

(2010) Bhuvanesh Dave et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma

(2010) Gloria Peiró et al.   MODERN PATHOLOGY

MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells

(2009) Shawn P. Fessler et al.   BREAST CANCER RESEARCH AND TREATMENT

Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab

(2009) E. Yao et al.   CLINICAL CANCER RESEARCH

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

(2008) M. Untch et al.   ANNALS OF ONCOLOGY

Low activation of Insulin-like Growth Factor 1-Receptor (IGF1R) is associated with local recurrence in early breast carcinoma

(2008) Gloria Peiró et al.   BREAST CANCER RESEARCH AND TREATMENT

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

Targeted therapies in breast cancer: Where are we now?

(2008) Serena Di Cosimo et al.   EUROPEAN JOURNAL OF CANCER

Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy

(2008) Paul L. Nguyen et al.   JOURNAL OF CLINICAL ONCOLOGY

A Minimal Fragment of MUC1 Mediates Growth of Cancer Cells

(2008) Sanjeev Mahanta et al.   PLoS One

MUC1* Mediates the Growth of Human Pluripotent Stem Cells

(2008) Sherry T. Hikita et al.   PLoS One

Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas

(2008) Enrique Lerma et al.   VIRCHOWS ARCHIV